207940 — Samsung Biologics Co Income Statement
0.000.00%
Last trade - 00:00- KR₩74tn
- KR₩74tn
- KR₩5tn
Annual income statement for Samsung Biologics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,164,777 | 1,568,007 | 3,001,295 | 3,694,589 | 4,547,322 |
| Cost of Revenue | |||||
| Gross Profit | 416,076 | 726,451 | 1,468,448 | 1,802,765 | 2,290,845 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 873,343 | 1,030,697 | 1,952,562 | 2,575,750 | 3,289,039 |
| Operating Profit | 291,434 | 537,310 | 1,048,733 | 1,118,839 | 1,258,283 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 265,992 | 561,283 | 1,009,025 | 1,119,987 | 1,370,052 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 240,975 | 393,589 | 798,056 | 857,691 | 1,083,316 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 240,975 | 393,589 | 798,056 | 857,691 | 1,083,316 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 240,975 | 393,589 | 798,056 | 857,691 | 1,083,316 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3,643 | 5,957 | 10,724 | 12,037 | 15,931 |
| Dividends per Share |